Johnson & Johnson (JNJ) Free Cash Flow (2009 - 2026)
Johnson & Johnson (JNJ) posted Free Cash Flow of $1.5 billion for Q1 2026, down 73.23% sequentially from $5.5 billion in Q4 2025, and down 56.64% YoY from $3.4 billion in Q1 2025.
Johnson & Johnson (JNJ) Free Cash Flow (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Free Cash Flow data on file, last reported at $1.5 billion in Q1 2026.
- Quarterly Free Cash Flow fell 56.64% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 billion (down 12.7% YoY) and the FY2025 annual result came in at $19.7 billion, down 0.73% from the prior year.
- Free Cash Flow slipped to $1.5 billion in Q1 2026 per JNJ's latest filing, from $5.5 billion in the prior quarter.
- The five-year high for Free Cash Flow was $8.0 billion in Q3 2025, with the low at $1.5 billion in Q1 2026.
- Average Free Cash Flow over 5 years is $4.3 billion, with a median of $3.4 billion recorded in 2025.
- Year-over-year, Free Cash Flow soared 259.75% in 2023 and tumbled 56.64% in 2026.
- Johnson & Johnson's Free Cash Flow stood at $3.4 billion in 2022, then jumped by 86.06% to $6.3 billion in 2023, then decreased by 14.39% to $5.4 billion in 2024, then grew by 1.88% to $5.5 billion in 2025, then plunged by 73.23% to $1.5 billion in 2026.
- Business Quant data shows JNJ's Free Cash Flow at $1.5 billion in Q1 2026, $5.5 billion in Q4 2025, and $8.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.01 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.47 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.56 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 547.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 346.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 594.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 1.47 Bn |
| Mar 29, 2026 | 1.47 Bn |
| Dec 28, 2025 | 5.47 Bn |
| Dec 28, 2025 | 5.47 Bn |
| Sep 28, 2025 | 8.01 Bn |
| Sep 28, 2025 | 8.01 Bn |
| Jun 29, 2025 | 2.84 Bn |
| Jun 29, 2025 | 2.84 Bn |
| Mar 30, 2025 | 3.38 Bn |
| Mar 30, 2025 | 3.38 Bn |
| Dec 29, 2024 | 5.37 Bn |
| Dec 29, 2024 | 5.37 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Mar 31, 2024 | 2.85 Bn |
| Mar 31, 2024 | 2.85 Bn |
| Dec 31, 2023 | 6.27 Bn |
| Dec 31, 2023 | 6.27 Bn |